

# RESULTS



## Results

The results of the present study were summarized, statistically analyzed and presented in (11) tables and (10) figures.

**Table (12): Age distribution among the study population.**

Age (Year)	Patients (N=21)	Control (N=20)
Mean $\pm$ SD	47.43 $\pm$ 10.67	49.2 $\pm$ 8.54
T value	0.588	
P value	0.560	

The mean age of the patient group was 47.43.  $\pm$  10.67 years while, the mean age of the control group was 49.22  $\pm$  8.54 years. The analysis of difference between the age in patients and control groups was statistically non significant ( $P > 0.05$ ).

**Table (13): Sex distribution among the study population.**

<b>Sex</b>	<b>Patients (N=21)</b>	<b>Controls (N=20)</b>
<b>Males</b>	17 (80.95%)	12 (60%)
<b>Females</b>	4 (19.05%)	8 (40%)

Pearson Chi - Square

Value = 2.17

df= 1

P = 0.141

The patients group included 21 patients with chronic hepatitis C 17 males (80.95%) and 4 females (19.05%). The control group included 20 HCV - negative individual 12 males 12 (60%) and 8 females 8 (40%). The analysis of difference between the sex among patients and control groups was statistically non significant ( $P > 0.05$ ).

**Table (14) Analysis of difference between surface markers of the peripheral blood lymphocytes (PBL) in patients and control group (unpaired t- test):**

<b>Surface marker (%)</b>	<b>Patients (N=21) Mean <math>\pm</math> SD</b>	<b>Control (N=20) Mean <math>\pm</math> SD</b>	<b>t value</b>	<b>P value</b>
- T – cell				
CD3 <sup>+</sup>	65.6 $\pm$ 9.52	60.9 $\pm$ 4.8	2.046	0.051
CD4 <sup>+</sup>	44.1 $\pm$ 7.32	35.7 $\pm$ 3.34	4.664	0.001
CD8 <sup>+</sup>	22.1 $\pm$ 8.32	25.2 $\pm$ 3.7	-1.583	0.125
CD4 <sup>+</sup> / CD8 <sup>+</sup> ratio	2.39 $\pm$ 1.1	1.45 $\pm$ 0.27	3.776	0.001
- B – cell (CD19 <sup>+</sup> )	6.17 $\pm$ 3.14	5.97 $\pm$ 2.26	1.42	0.21
- NK (CD56 <sup>+</sup> )	14.02 $\pm$ 5.04	12.65 $\pm$ 3.59	1.07	0.316

This table shows the mean  $\pm$  SD of the surface markers of the PBL in patients and control groups. There was a statistically significant difference between the proportion of the peripheral blood CD4<sup>+</sup> and CD4<sup>+</sup> / CD8<sup>+</sup> ratio among the patients and the control groups. There was no statistically significant difference between the proportion of CD3<sup>+</sup>, CD8<sup>+</sup>, CD19<sup>+</sup> and CD56<sup>+</sup> (NK) in patients and control groups.

**Table (15) Analysis of difference between surface markers of the intrahepatic lymphocytes (IHL) in patients and control groups (unpaired t-test):**

<b>Surface marker (%)</b>	<b>Patients (N=21) Mean <math>\pm</math> SD</b>	<b>Control (N=20) Mean <math>\pm</math> SD</b>	<b>t value</b>	<b>P value</b>
- T – cell				
CD3 <sup>+</sup>	61.23 $\pm$ 14.29	60.34 $\pm$ 12.16	0.218	0.828
CD4 <sup>+</sup>	18.07 $\pm$ 8.54	10.3 $\pm$ 3.53	3.923	0.001
CD8 <sup>+</sup>	43.19 $\pm$ 10.29	50.36 $\pm$ 10.36	-2.223	0.032
CD4 <sup>+</sup> / CD8 <sup>+</sup> ratio	0.43 $\pm$ 0.21	0.20 $\pm$ 0.06	4.020	0.001
-B– cells (CD19 <sup>+</sup> )	5.15 $\pm$ 2.7	3.78 $\pm$ 1.79	1.903	0.065
- NK cells	24.97 $\pm$ 7.38	18.27 $\pm$ 3.16	3.72	0.001

There was a statistically significant difference between the proportion of intrahepatic CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup> / CD8<sup>+</sup> ratio and NK lymphocytes in patients and control groups.

There was no statistically significant difference between the proportion of intrahepatic CD3<sup>+</sup> & CD19<sup>+</sup> lymphocytes in both groups.

**Table (16) Analysis of difference between surface markers of peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes (IHL) in patients group (Paired t-test):**

<b>Patients (N=21)</b>				
<b>Surface marker (%)</b>	<b>PBL Mean <math>\pm</math> SD</b>	<b>IHL Mean <math>\pm</math> SD</b>	<b>t value</b>	<b>P value</b>
- T – cell				
CD3 <sup>+</sup>	65.64 $\pm$ 9.5	61.2 $\pm$ 14.2	1.688	0.107
CD4 <sup>+</sup>	43.95 $\pm$ 7.3	18.06 $\pm$ 8.5	18.416	0.001
CD8 <sup>+</sup>	22.12 $\pm$ 8.3	43.19 $\pm$ 10.3	3.663	0.001
CD4 <sup>+</sup> / CD8 <sup>+</sup>	2.38 $\pm$ 1.11	0.4 $\pm$ 0.22	8.33	0.001
-B– cells (CD19 <sup>+</sup> )	6.17 $\pm$ 4.1	5.15 $\pm$ 2.7	1.12	0.12
- NK (CD56 <sup>+</sup> )	14.02 $\pm$ 5.03	24.97 $\pm$ 7.38	5.08	0.001

There was a significant positive difference between intrahepatic (IHL) and peripheral blood (PBL) CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup> / CD8<sup>+</sup> ratio and NK cells proportions among the patients group ( $P < 0.05$ ). There was no significant difference between (PB) & (IH) CD3<sup>+</sup>, CD19<sup>+</sup> in patients group ( $P > 0.05$ ).

**Table (17) Correlation between surface markers of the peripheral blood lymphocytes (PBL) and histopathological activity of hepatitis C evaluated by Knodell's score:**

Surface marker of (PBL)	Knodell's score	
	r	P
CD3	0.598	0.004*
CD4	0.763	0.000**
CD8	-0.002	0.993
CD4/ CD8 ratio	0.213	0.353
CD19	0.230	0.316
CD56	-0.250	0.275

There was a statistically significant positive correlation between the peripheral blood CD3, CD4 and Knodell's score in patients group ( $P < 0.05$ ). . There was no statistically significant correlation between knodell's score and blood CD8, CD19 and CD56 in patients group.

**Table (18) Correlation between surface markers of intrahepatic lymphocytes (IHL) and histopathological activity of hepatitis C (HA) evaluated by Knodell's score:**

Surface marker (IHL)	Knodell's Score	
	r	P
CD3	0.577	0.006*
CD4	0.894	0.000**
CD8	0.056	0.809
CD4/ CD8 ratio	0.840	0.000**
CD19	-0.040	0.864
CD56	0.155	0.502

There was a statistically significant positive correlation between the intrahepatic CD4, CD4 / CD8 ratio and CD3 and the Knodell's score in patients group. There was no statistically significant positive correlation between intrahepatic CD8, CD19 and CD56 and Knodell's score in patients group.



**Table (19) Correlation between ALT & AST levels and surface markers of the peripheral blood lymphocytes (PBL) in patients group:**

Surface marker of (PBL)	ALT (U/L)		AST (U/L)	
	R	p	r	P
CD3	-0.245	-0.284	-0.773	0.096
CD4	-0.065	0.779	-0.278	0.223
CD8	-0.212	0.357	-0.129	0.576
CD4/ CD8 ratio	0.148	0.523	-0.042	0.857
CD19	-0.296	0.192	-0.516	0.067
CD56	-0.126	0.587	-0.046	0.843

No significant correlation was found between ALT & AST levels and the surface markers of the blood lymphocytes.

**Table (20) Ccorrelation between ALT & AST levels and surface markers of intrahepatic lymphocytes in patients group:**

Surface marker of (IHL)	ALT (U/L)		AST (U/L)	
	R	p	r	P
CD3	-0.107	0.643	-0.254	0.266
CD4	0.018	0.938	-0.233	0.309
CD8	-0.165	0.475	-0.161	0.487
CD4/ CD8 ratio	0.091	0.696	-0.138	0.551
CD19	-0.367	0.102	-0.493	0.063
CD56	-0.289	0.203	-0.124	0.593


No significant correlation was found between the levels of ALT & AST and the of intrahepatic lymphocytes in patient group.

Table (21): Descriptive data of the control group:


Parameter	Mean $\pm$ SD	Range		Unit
		Min	Max	
Age	49.2 $\pm$ 8.54	37	64	Year
S. Protein	7.53 $\pm$ 0.39	6.9	8.1	gm/dl
S. Albumin	4.43 $\pm$ 0.44	3.8	5.0	gm/dl
ALT	33.6 $\pm$ 8.56	22	45.0	u/l
AST	28.30 $\pm$ 6.96	20	40.0	u/l
Prothrombin time	13.3 $\pm$ 0.23	12.7	14.2	Seconds
WBcs	6.24 $\pm$ 1.76	4.1	10.0	Thousands/cmm
RBcs	4.98 $\pm$ 0.39	4.4	5.8	Million/cmm
Hb	13.5 $\pm$ 1.50	12.1	16.1	gm/dl
Platelets	203 $\pm$ 22.99	175	250	Thousands/cmm
Lymphocytes	1.6 $\pm$ 0.56	1.0	2.7	Thousands/cmm
CD3 (Blood)	60.86 $\pm$ 4.78	51.6	70.1	%
CD4 (Blood)	35.7 $\pm$ 3.34	31.5	41.1	%
CD8 (blood)	25.28 $\pm$ 3.69	19.8	30.5	%
CD4/CD8 ratio (Blood)	1.45 $\pm$ 0.27	1.7	2.1	%
CD19 (Blood)	5.97 $\pm$ 3.14	2.5	9.1	%
CD56 (Blood)	12.64 $\pm$ 3.59	7.2	20.1	%
CD3 (IH)	60.33 $\pm$ 12.16	40.3	77	%
CD4 (IH)	10.13 $\pm$ 3.53	4.5	17.1	%
CD8 (IH)	50.36 $\pm$ 10.36	35.1	63.5	%
CD4/CD8 ratio (IH)	0.200 $\pm$ 0.06	0.1	0.3	%
CD19 (IH)	3.78 $\pm$ 1.8	1	7.4	%
CD56 (IH)	18.27 $\pm$ 3.16	12.2	26.8	%

Table (22) Descriptive data of the patients group:

Parameter	Mean $\pm$ SD	Range		Unit
		Min	Max	
Age	47.4 $\pm$ 10.67	35	64	Year
S. Protein	7.77 $\pm$ 0.48	6.3	8.5	gm/dl
S. Albumin	4.7 $\pm$ 0.7	2.3	5.7	gm/dl
S. Bilirubin	0.91 $\pm$ 0.35	0.5	1.9	Mg/e
ALT	74.7 $\pm$ 17.4	40	109	u/e
AST	35.6 $\pm$ 20.5	20	48	u/l
Prothrombin time	13.1 $\pm$ 0.98	12	15	Seconds
Prothrombin Conc.	83.9 $\pm$ 13.3	61	100	%
Wbcs	6.5 $\pm$ 2.6	1.7	12.3	Thousands/cmm
Rbcs	3.9 $\pm$ 0.4	3.2	4.7	Million/cmm
Platelets	211.6 $\pm$ 69.1	85	329	Thousands/cmm
Hb	12.2 $\pm$ 2.4	6.7	16	gm/dl
Lymphocytes	1.5 $\pm$ 0.55	0.8	3	Thousands/cmm
CD3 (Blood)	65.65 $\pm$ 9.53	46.1	83	%
CD4 (Blood)	43.96 $\pm$ 7.33	26.1	56.7	%
CD8 (blood)	22.13 $\pm$ 8.32	10.2	36	%
CD4/CD8 ratio (Blood)	2.38 $\pm$ 1.11	1	4	%
CD19 (Blood)	6.17 $\pm$ 3.14	4.4	10.8	%
CD56 (Blood)	14.02 $\pm$ 5.04	4.6	26.3	%
CD3 (IH)	61.24 $\pm$ 14.29	41	86	%
CD4 (IH)	18.06 $\pm$ 8.54	10.0	35.0	%
CD8 (IH)	43.19 $\pm$ 10.29	28	64	%
CD4/CD8 ratio (IH)	0.43 $\pm$ 0.22	0.2	0.96	%
CD19 (IH)	5.15 $\pm$ 2.73	1.5	10.5	%
CD56 (IH)	24.97 $\pm$ 7.38	18	33.4	%
Knodell score	4.7 $\pm$ 3.4	1	13	%




**Fig. (25): Sex distribution in patient group.**




**Fig(26) Peripheral blood lymphocytes in patients and control groups.**

There was a statistically significant difference between the proportion of PBL  $CD4^+$  and  $CD4^+/CD8^+$  in patients and control groups ( $P < 0.05$ ). While, there was no statistically significant difference between the proportion of  $CD3^+$ ,  $CD8^+$ ,  $CD19^+$  and  $CD 56^+$  (NK) cells in patients and control groups ( $P > 0.05$ ).



**Fig(27) Intrahepatic lymphocytes in patients and control groups**


There was a statistically significant difference between the proportion of intrahepatic CD4+, CD8+, CD4+/CD8+ ratio and NK lymphocytes in patients and control groups ( $P < 0.05$ ). There was no statistically significant difference between the proportion of intrahepatic CD3+ and CD 19+ lymphocytes in patients and control group ( $P > 0.05$ ).



**Fig. (28): Peripheral blood and intrahepatic lymphocytes in patients group.**


There was a statistically significant difference between the intrahepatic and peripheral blood CD4+, CD8+ and NK cells among patients group ( $P < 0.05$ ). There was no statistically significant difference between the peripheral blood and intrahepatic CD3+, CD19+ among patients group ( $P > 0.05$ ).






**Fig. (29): Correlation between peripheral blood CD4 lymphocytes and Knodell's score in patients group.**

There was a statistically significant positive correlation between Knodell's score & CD4+ in patients group ( $P < 0.05$ ). There was no statistically significant correlation between Knodell's score and CD8+ CD19+, CD56+ (PBL) in patients group.




**Fig. (30): Correlation between intrahepatic CD4+ lymphocytes and Knodell's score in patients group.**

There was a statistically significant positive correlation between Knodell's score & IH CD4, in patients group ( $P < 0.05$ ). There was no significant correlation between Knodell's score and CD8+ CD19+, CD56+ (IHL) in patients group.




**Fig. (31): Correlation between peripheral blood CD3 lymphocytes and knodell's score in patients group.**

There was a statistically significant positive correlation between Knodell's score & CD3+ PBL in patients group ( $P < 0.05$ ).




**Fig. (32): Correlation between intrahepatic CD3 lymphocytes and Knodell's score in patients group.**

There was a statistically significant positive correlation between Knodell's score & CD3+ IHL in patients group ( $P < 0.05$ ).



**Fig. (33): Correlation between peripheral blood CD4<sup>+</sup>/CD8<sup>+</sup> lymphocytes and Knodell's score in patients group.**

No statistically positive correlation was found between peripheral blood CD4<sup>+</sup>/CD8<sup>+</sup> ratio and Knodell's score in patients.



**Fig. (34): Correlation between intrahepatic CD4<sup>+</sup>/CD8<sup>+</sup> lymphocytes and Knodell's score in patients group.**

There was statistically positive correlation between IH CD4<sup>+</sup>/CD8<sup>+</sup> ratio and Knodell's score in patients.